Feature | September 13, 2013| Dave Fornell

Vascular Closure Devices Aid Closure of Large Access Sites

Off-label use of closure devices speeds hemostasis following TEVAR, TAVR and pVAD use

There is no shortage of debate among interventional cardiologists over whether vascular closure devices should be used for standard cath lab procedures. However, some say these devices have a definite niche in areas where they were not originally intended but have found frequent off-label use because of their utility. 

The larger sizes of devices used for transcatheter endovascular aortic repair (TEVAR) and transcatheter aortic valve replacement (TAVR) requires a much larger arteriotomy site than standard percutaneous coronary interventions (PCI). However, these larger holes also make it more difficult to achieve hemostasis using manual compression alone. 

Some of these devices are as large as 24 French, and anything larger requires a surgical cut-down, said Chris Malaisrie, M.D., assistant professor of surgery, division of cardiac surgery, Northwestern University Memorial Hospital, Chicago. “You can’t just hold pressure on a hole that size,” Malaisrie explained. “I use the preclose technique for large bore access for TEVAR and TAVI. I currently use Abbott Prostar or Abbott Perclose Proglide off-label. I prefer the ProGlide, even though you need two of them to close.”

The Abbott Perclose ProGlide suture-mediated closure system provides a suture for vascular closure of 5 – 21 French femoral artery access sites. The vendor says for sheath sizes greater than 8 French, at least two devices and the pre-close technique are required. The system helps reduce time to hemostasis, ambulation and discharge. 

Another off-label application of these devices has been found when using percutaneous ventricular assist devices (pVADs), such as the Abiomed Impella or the CardiacAssist TandemHeart systems. The TandemHeart system uses cannula sizes up to 17 French. 

“We primarily use two ProGlides for Impella 13 French closure using an off-label pre close technique,” said Mladen Vidovich, M.D., FACC, FSCAI, chief, section of cardiology, Jesse Brown VA Medical Center, and associate professor of medicine, University of Illinois, Chicago. 

He said cath labs at both Jesse Brown VA and UIC used closure devices on a regular basis for femoral access PCI in the past to speed patient ambulation and cut nursing time. However, he said both facilities have drastically reduced the need for these devices. 

“Due to our high radial access volume, our closure device use has dwindled, but for the rare groin I’ll use Proglide,” Vidovich said.   

Related Content

Medtronic, CoreValve Evolut R, TAVR system, 34 mm valve, FDA approval, largest in the U.S.
Technology | Heart Valve Technology| October 26, 2016
Medtronic announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve Evolut R 34...
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano
News | Heart Valve Technology| October 10, 2016
Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and...
Northwestern Medicine, Edwards Lifesciences, Intuity Elite suturless aortic valve, first in Illinois

Edwards Intuity valve image courtesy of Northwestern Medicine

News | Heart Valve Technology| October 07, 2016
October 7, 2016 — A Northwestern Medicine cardiac surgeon was recently the first in Illinois and second in the United
Xeltis bioabsorbable valve implant, two-year data, EACTS 2016
News | Heart Valve Technology| October 06, 2016
October 6, 2016 — Xeltis announced this week that patients...
Heartware HVAD, ventricular assist device, artificial heart, Medtronic
News | October 05, 2016
October 5, 2016 — Medtronic said two previously communicated global voluntary recalls related to the HeartWare Intern
Xeltis bioabsorbable pulmonary heart valve, Xplore-I clinical feasibility study, first pediatric implants, EACTS 2016
News | Heart Valve Technology| October 04, 2016
October 4, 2016 — Xeltis recently announced that three pediatric patients have been successfully implanted with the w
Sponsored Content | Videos | Congenital Heart| October 04, 2016
Xeltis, a Swiss-Dutch clinical-stage medical device company, recently implanted three pediatric patients with the wor
Keystone Heart, TriGuard Embolic Protection Device, Neuro-TAVR study, brain lesions, American Journal of Cardiology
News | Heart Valve Technology| October 03, 2016
Keystone Heart Ltd. announced data recently published in the American Journal of Cardiology demonstrating new brain...
Overlay Init